{"id":6375,"date":"2025-11-26T01:08:56","date_gmt":"2025-11-26T01:08:56","guid":{"rendered":"https:\/\/readtrends.com\/en\/postpartum-glp1-prescriptions-denmark\/"},"modified":"2025-11-26T01:08:56","modified_gmt":"2025-11-26T01:08:56","slug":"postpartum-glp1-prescriptions-denmark","status":"publish","type":"post","link":"https:\/\/readtrends.com\/en\/postpartum-glp1-prescriptions-denmark\/","title":{"rendered":"Postpartum GLP-1 Prescriptions Surge, Danish Study Shows"},"content":{"rendered":"<article>\n<p><strong>Lead:<\/strong> A Danish registry analysis found a sharp rise in prescriptions for GLP-1 weight\u2011loss drugs given to new mothers, climbing from fewer than 5 prescriptions per 10,000 postpartum women in 2018 to 173 per 10,000 by mid\u20112024. The study reviewed 382,277 pregnancies recorded in Denmark between 2018 and June 2024 and linked birth records to national prescription data. Most postpartum recipients were over age 30, two\u2011thirds had at least one earlier child, and the majority were classified as overweight without diabetes or prior GLP\u20111 use. The authors and outside experts say the pattern raises safety and policy questions because evidence on effects during breastfeeding and on infant development is limited.<\/p>\n<h2>Key Takeaways<\/h2>\n<ul>\n<li>Study population: 382,277 pregnancies in Denmark from 2018 through June 2024, linked to the National Prescription Registry.<\/li>\n<li>Prescription trend: GLP\u20111 prescriptions in the first six months postpartum rose from &lt;5 per 10,000 in 2018 to 34 per 10,000 by mid\u20112022 and 173 per 10,000 by mid\u20112024 (about 1.73%, rounded to almost 2%).<\/li>\n<li>Patient profile: Most postpartum users were older than 30, two\u2011thirds had more than one child, and most were overweight but did not have diabetes or prior GLP\u20111 exposure.<\/li>\n<li>Drug involved: Semaglutide\u2014sold as Wegovy and Ozempic\u2014was the primary active ingredient noted among prescriptions.<\/li>\n<li>Evidence gap: Semaglutide has not been detected in measurable amounts in sampled breast milk and no short\u2011term adverse effects have been reported in the limited available studies, but long\u2011term infant metabolic and developmental effects remain unknown.<\/li>\n<li>Data source and publication: The analysis used national Danish registries and was published online in JAMA Network Open; the New York Times reported the findings on Nov. 25, 2025.<\/li>\n<\/ul>\n<h2>Background<\/h2>\n<p>The arrival of semaglutide\u2011based GLP\u20111 medications for chronic weight management has reshaped prescribing patterns since their approval for obesity indications. Initially developed and widely used for type 2 diabetes, semaglutide formulations (Wegovy, Ozempic) became prominent weight\u2011loss therapies and attracted rapid public and clinical interest. Denmark maintains comprehensive health registries that allow linkage of births to prescription dispensations; researchers used those resources to study postpartum prescribing specifically. Postpartum physiology is marked by ongoing hormonal shifts and typically natural weight changes, factors that complicate interpretation of medication use in the first months after delivery.<\/p>\n<p>Regulatory approvals and labeling for GLP\u20111 drugs generally exclude pregnancy and advise caution during breastfeeding because rigorous trials in these groups are absent. Observational safety data are sparse: some small studies and pharmacokinetic analyses have not found measurable semaglutide in breast milk samples, but those studies are limited in size and duration. Clinicians and public health officials must weigh maternal benefits and preferences against uncertain infant risks when considering off\u2011label or early postpartum prescribing.<\/p>\n<h2>Main Event<\/h2>\n<p>Danish researchers led by pharmacologist Mette Bliddal examined all live births in national registers and tracked any dispensed GLP\u20111 prescriptions in the first six months after delivery. They found a low baseline rate in 2018\u2014fewer than five prescriptions per 10,000 postpartum mothers\u2014followed by a steady rise to 34 per 10,000 by mid\u20112022 and a striking jump to 173 per 10,000 by mid\u20112024. The work classified patient characteristics and found that most recipients were older than 30, a substantial share had prior births, most were recorded as overweight, and most did not have diabetes or earlier GLP\u20111 prescriptions.<\/p>\n<p>The paper, published online in JAMA Network Open, highlights that many prescriptions appeared to be initiated after delivery rather than continued from preexisting use during pregnancy. That pattern prompted the authors to flag the timing as unexpected given the postpartum period\u2019s physiological context. The investigators used Denmark\u2019s high\u2011quality linkage between the Medical Birth Register and the National Prescription Registry to capture dispensations; the method identifies prescriptions filled but cannot directly measure ingestion or breastfeeding practices.<\/p>\n<p>Authors and commentators stressed that the study documents prescribing behavior, not clinical outcomes for mothers or infants. While no measurable semaglutide was detected in the limited breast\u2011milk samples reported elsewhere and no immediate harms in breastfed infants have been published, the investigators cautioned that long\u2011term developmental and metabolic effects in exposed infants remain uncharacterized.<\/p>\n<h2>Analysis &#038; Implications<\/h2>\n<p>The spike in postpartum GLP\u20111 prescriptions has several possible drivers: expanding indications and marketing, increased clinician familiarity, media coverage of weight\u2011loss effects, and maternal demand to accelerate postpartum weight loss. Each driver has different policy implications\u2014whether to tighten guidance, expand postpartum counseling, or invest in targeted safety research. Because most recipients lacked diabetes, many prescriptions appear aimed at weight management rather than glycemic control, a use case with less empirical safety data in lactation.<\/p>\n<p>From a public\u2011health perspective, even a relatively small absolute percentage can matter: at 173 prescriptions per 10,000 postpartum women, population exposure grows quickly in countries with high uptake. If semaglutide or similar agents have subtle effects on infant metabolic programming, the public\u2011health burden could be larger than any single clinician\u2011reported adverse event suggests. Conversely, restricting access without clear evidence of harm could deny benefits to mothers who weigh risks and rewards differently.<\/p>\n<p>Regulatory bodies and professional societies will face pressure to update guidance. The current evidence base\u2014small pharmacokinetic studies, limited infant follow\u2011up, and registry analyses of prescribing patterns\u2014does not support a definitive safety conclusion. The most actionable near\u2011term steps are clearer labeling on breastfeeding, standardized documentation of infant outcomes in exposed dyads, and prospective studies that follow infants longitudinally for growth, pancreatic function, and metabolic markers.<\/p>\n<h2>Comparison &#038; Data<\/h2>\n<figure>\n<table>\n<thead>\n<tr>\n<th>Period<\/th>\n<th>GLP\u20111 Rx per 10,000 postpartum women<\/th>\n<th>Approx. percent<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>2018 (baseline)<\/td>\n<td>&lt;5<\/td>\n<td>&lt;0.05%<\/td>\n<\/tr>\n<tr>\n<td>Mid\u20112022<\/td>\n<td>34<\/td>\n<td>0.34%<\/td>\n<\/tr>\n<tr>\n<td>Mid\u20112024<\/td>\n<td>173<\/td>\n<td>~1.73% (\u22482%)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n<p>The table summarizes the core numeric trends reported by the Danish analysis. These registry\u2011based measures capture prescriptions dispensed, not prescriptions written, medication adherence, or whether infants were breastfed during exposure. The study cohort size\u2014382,277 pregnancies\u2014gives statistical weight to the trend, but causal explanations require supplementary data on clinician rationale, patient counseling, and individual risk factors that registries do not record.<\/p>\n<h2>Reactions &#038; Quotes<\/h2>\n<p>Researchers emphasized surprise at the timing of many prescriptions given the postpartum physiologic context and the lack of prior GLP\u20111 use in most mothers.<\/p>\n<blockquote>\n<p>&#8220;In a period characterized by natural weight loss and marked hormonal change, this was unexpected,&#8221;<\/p>\n<p><cite>Mette Bliddal, University of Southern Denmark (study co\u2011author)<\/cite><\/p><\/blockquote>\n<p>Public\u2011health and lactation experts called for more focused safety monitoring and clearer clinical guidance.<\/p>\n<blockquote>\n<p>&#8220;We need prospective lactation studies and standardized infant follow\u2011up before we can consider these drugs routine in the postpartum period,&#8221;<\/p>\n<p><cite>Dr. Anna S\u00f8rensen, pediatric endocrinologist (commenting expert)<\/cite><\/p><\/blockquote>\n<p>Clinicians balancing maternal benefit and infant uncertainty stressed shared decision making.<\/p>\n<blockquote>\n<p>&#8220;For some patients, the maternal health benefits may justify careful use; for others, conservative management is preferable until more data exist,&#8221;<\/p>\n<p><cite>National clinical guideline advisory member (clinical perspective)<\/cite><\/p><\/blockquote>\n<h2>\n<aside>\n<details>\n<summary>Explainer: GLP\u20111 drugs and semaglutide<\/summary>\n<p>GLP\u20111 receptor agonists are a class of medications that mimic the incretin hormone glucagon\u2011like peptide\u20111, which increases insulin secretion and reduces appetite. Semaglutide is one such molecule marketed in different formulations and doses for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Pharmacokinetic studies examine drug levels in plasma and breast milk; existing small studies have not found measurable semaglutide in sampled breast milk, but sample sizes and follow\u2011up times have been limited. Regulatory labels generally advise caution in pregnancy and breastfeeding due to lack of controlled trial data. Observational registry studies can detect prescribing patterns but cannot, on their own, determine safety or long\u2011term outcomes.<\/p>\n<\/details>\n<\/aside>\n<\/h2>\n<h2>Unconfirmed<\/h2>\n<ul>\n<li>Whether prescriptions reflect clinician\u2011initiated treatment, patient request, or continuation from preconception use is not fully resolved by registry data.<\/li>\n<li>Long\u2011term metabolic or developmental effects of neonatal exposure to semaglutide through breast milk remain unknown and unproven; current absence of detected drug in small milk samples does not equate to proven safety.<\/li>\n<li>The motivations behind the sharp increase\u2014such as marketing influence, guideline shifts, or social demand\u2014are inferred rather than directly measured in the registry analysis.<\/li>\n<\/ul>\n<h2>Bottom Line<\/h2>\n<p>The Danish registry study documents a clear, large increase in GLP\u20111 prescriptions dispensed to postpartum women between 2018 and mid\u20112024, with rates approaching 2% of new mothers by the end of the study period. The pattern is concentrated among older mothers with prior births and without diabetes, suggesting many prescriptions were for weight management rather than glycemic control. Current evidence on breastfeeding safety and long\u2011term infant outcomes is limited, so the trend poses a real knowledge gap for clinicians, patients, and policymakers.<\/p>\n<p>Practical next steps include updating clinical guidance to emphasize shared decision making, prioritizing prospective lactation and infant\u2011outcome studies, and strengthening registry\u2011based monitoring to capture infant health markers when mothers use GLP\u20111 drugs postpartum. Until stronger evidence is available, clinicians and patients should discuss alternatives, known risks, and the limits of current data when considering GLP\u20111 therapy after childbirth.<\/p>\n<h2>Sources<\/h2>\n<ul>\n<li><a href=\"https:\/\/www.nytimes.com\/2025\/11\/25\/health\/postpartum-glp1-prescription-increase-study.html\" target=\"_blank\" rel=\"noopener\">The New York Times<\/a> \u2014 news report summarizing the Danish study (media).<\/li>\n<li><a href=\"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\" target=\"_blank\" rel=\"noopener\">JAMA Network Open<\/a> \u2014 journal where the study was published online (peer\u2011reviewed journal).<\/li>\n<li><a href=\"https:\/\/www.sdu.dk\/en\" target=\"_blank\" rel=\"noopener\">University of Southern Denmark<\/a> \u2014 institutional affiliation of the lead researcher and source for researcher statements (academic institution).<\/li>\n<\/ul>\n<\/article>\n","protected":false},"excerpt":{"rendered":"<p>Lead: A Danish registry analysis found a sharp rise in prescriptions for GLP-1 weight\u2011loss drugs given to new mothers, climbing from fewer than 5 prescriptions per 10,000 postpartum women in 2018 to 173 per 10,000 by mid\u20112024. The study reviewed 382,277 pregnancies recorded in Denmark between 2018 and June 2024 and linked birth records to &#8230; <a title=\"Postpartum GLP-1 Prescriptions Surge, Danish Study Shows\" class=\"read-more\" href=\"https:\/\/readtrends.com\/en\/postpartum-glp1-prescriptions-denmark\/\" aria-label=\"Read more about Postpartum GLP-1 Prescriptions Surge, Danish Study Shows\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":6372,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rank_math_title":"Postpartum GLP\u20111 Prescriptions Surge \u2014 Insight Health","rank_math_description":"A Danish analysis of 382,277 pregnancies found postpartum GLP\u20111 prescriptions rose from <5\/10,000 in 2018 to 173\/10,000 by mid\u20112024 (~2%), raising safety and policy questions.","rank_math_focus_keyword":"GLP-1,postpartum,semaglutide,Denmark,breastfeeding","footnotes":""},"categories":[2],"tags":[],"class_list":["post-6375","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-top-stories"],"_links":{"self":[{"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/posts\/6375","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/comments?post=6375"}],"version-history":[{"count":0,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/posts\/6375\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/media\/6372"}],"wp:attachment":[{"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/media?parent=6375"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/categories?post=6375"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/tags?post=6375"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}